生物科技公司Equillium, Inc. (NASDAQ: EQ )，目前市值2,515万美元，股价0.71美元，今日宣布其用于治疗中重度溃疡性结肠炎 (UC)的药物itolizumab二期临床试验取得积极结果。

Though the baseline illness severity was uneven, with more severe patients in the itolizumab arm, the medication showed great ...

In a mid-stage study, the candidate itolizumab achieved 23.3% clinical remission rate at 12 weeks, numerically better than ...

Equillium, Inc. (EQ) appears an attractive pick, as it has been recently upgraded to a Zacks Rank #2 (Buy). This upgrade is essentially a reflection of an upward trend in earnings estimates -- one of ...

Equillium, Inc. (EQ) appears an attractive pick, as it has been recently upgraded to a Zacks Rank #2 (Buy). This upgrade is essentially a reflection of an upward trend in earnings estimates -- one ...

The study was co-sponsored by Equillium and Biocon Limited and conducted at multiple clinical trial sites in India. The design and conduct of the trial were a collaborative effort, with input from ...

Equillium, Inc. (NASDAQ:EQ – Free Report) – Investment analysts at Leerink Partnrs increased their FY2025 earnings estimates for shares of Equillium in a report released on Wednesday ...

Bengaluru: Equillium, Inc., a clinical-stage biotechnology company and Biocon Limited, an innovation-led global ...

Equillium (EQ) and Biocon announced topline results from the Phase 2 study evaluating itolizumab in the treatment of moderate to severe ...